Discontinued — last reported Q4 '25
Change in receivables
OperatingEli Lilly Change in receivables remained flat by 0.0% to $1.75B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 224.8%, from $538.80M to $1.75B. Over 4 years (FY 2021 to FY 2025), Change in receivables shows an upward trend with a 53.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2011
Last reportedQ4 2025
How to read this metric
Rising receivables relative to sales can signal issues with collections or a shift toward more liberal credit terms.
Detailed definition
The net change in amounts owed to the company by customers and third parties for goods sold or services rendered, includ...
Peer comparison
Standard for B2B and service-heavy companies like Oracle or Salesforce where billing cycles lag revenue recognition.
Metric ID:
cf_change_in_receivablesHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.28B | $299.60M | $2.45B | $2.16B | $7.00B |
| YoY Change | — | -76.6% | +718.1% | -12.1% | +224.8% |
Range$299.60M – $7.00B
CAGR+53.0%
Avg YoY Growth+213.6%
Median YoY Growth+106.4%
Change in receivables at Other Companies
Frequently Asked Questions
- What is Eli Lilly's change in receivables?
- Eli Lilly (LLY) reported change in receivables of $1.75B in Q4 2025.
- How has Eli Lilly's change in receivables changed year-over-year?
- Eli Lilly's change in receivables increased by 224.8% year-over-year, from $538.80M to $1.75B.
- What is the long-term trend for Eli Lilly's change in receivables?
- Over 4 years (2021 to 2025), Eli Lilly's change in receivables has grown at a 53.0% compound annual growth rate (CAGR), from $1.28B to $7.00B.
- What does change in receivables mean?
- The change in the amount of money customers owe the company for recent purchases.